Target Name: CDC20B
NCBI ID: G166979
Review Report on CDC20B Target / Biomarker Content of Review Report on CDC20B Target / Biomarker
CDC20B
Other Name(s): CDC20B variant 3 | cell division cycle 20 homolog B | G6VTS76519 | CDC20B variant 2 | CDC20 cell division cycle 20 homolog B | CDC20-like protein | cell division cycle 20B | cell division cycle protein 20 homolog B | Cell division cycle protein 20 homolog B (isoform 2) | CD20B_HUMAN | Cell division cycle 20B, transcript variant 2 | Cell division cycle protein 20 homolog B (isoform 3) | Cell division cycle 20B, transcript variant 3 | Cell division cycle protein 20 homolog B

CD20B: A Promising Drug Target and Biomarker for Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide, affecting millions of people. Chronic obstructive lung diseases (COPD) are a group of progressive lung diseases that primarily affect the airways, making it difficult to breathe. According to the World Health Organization (WHO), an estimated 1.1 billion people worldwide have COPD, with approximately 15% of the global population suffering from severe COPD. COPD not only affects the individual but also has a significant impact on the economy, with healthcare costs and lost productivity due to frequent hospitalizations and work absences.

CD20B, a protein expressed in the B cells of the immune system, has been identified as a potential drug target and biomarker for COPD. In this article, we will discuss the characteristics of CD20B, its potential as a drug target, and its potential as a biomarker for COPD.

Characteristics of CD20B

CD20B is a type-I transmembrane protein that is expressed in the B cells of the immune system. It is a glycoprotein with a molecular weight of approximately 180 kDa. CD20B is composed of two heavy chains and two light chains that are held together by disulfide bonds. The heavy chains contain four constant (C) regions and one variable (V) region, while the light chains contain one variable (V) region and one constant (C) region.

CD20B is involved in the development and maintenance of B cell function, as well as the regulation of immune responses. It is a critical receptor for the antigens CD11b and CD137, which are expressed by activated T cells. CD20B plays a role in regulating the activation, proliferation, and differentiation of B cells, as well as in regulating the production of antibodies.

CD20B has also been shown to be involved in the regulation of autoimmune diseases, including multiple sclerosis and rheumatoid arthritis. In addition, CD20B has been shown to be involved in the regulation of inflammation and fibrosis.

Potential as a Drug Target

CD20B has been identified as a potential drug target for COPD due to its involvement in the regulation of B cell function and the immune response. Potential therapeutic approaches for COPD may include the use of antibodies targeting CD20B, as well as the use of small molecules that can modulate B cell function and immune responses.

One approach to targeting CD20B in COPD is the use of monoclonal antibodies (mAbs) that can bind to CD20B and prevent it from interacting with its ligands, such as CD11b and CD137. MAbs have been shown to be effective in treating a variety of diseases, including cancer and autoimmune diseases. By targeting CD20B, researchers hope to improve lung function and reduce the risk of complications in COPD patients.

In addition to the use of mAbs, researchers are also exploring the use of small molecules that can modulate B cell function and immune responses. Small molecules that can bind to CD20B and modulate its activity have the potential to be used as therapeutic agents for COPD.

Potential as a Biomarker

CD20B has also been identified as a potential biomarker for COPD. The detection and quantification of CD20B in breath or blood samples can be used to monitor the severity of COPD and the effectiveness of therapeutic interventions.

Studies have shown that the levels of CD20B in breath and blood samples are significantly elevated in individuals with COPD compared to healthy individuals. In addition, studies have shown that the levels of CD20B in breath and blood samples are associated with the severity of COPD, as measured by spirometry results.

The levels of CD20B in urine have also been shown to be elevated in individuals with COPD compared to healthy individuals. In addition, studies have shown that the levels of CD20B in urine are associated with the severity of COPD, as measured by spirometry results.

Conclusion

CD20B is a protein expressed in the immune system that is involved in the regulation of B cell function and the immune response. Its potential as a drug target and biomarker for COPD has been identified and is being explored further by researchers. The use of monoclonal antibodies and small molecules that can modulate B cell function and immune responses may lead to new therapeutic approaches for the treatment of COPD. Further research is needed to fully understand the role of CD20B in COPD and to develop safe and effective therapeutic agents.

Protein Name: Cell Division Cycle 20B

The "CDC20B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC20B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3